A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy

Yasutada Akiba, Yoshiyuki Yamagishi, Syuka Mori, Tomoki Ueda, Junji Suzuki, Naoki Hosoe, Mikiko Izumiya, Hiromasa Takaishi, Hiroshi Nagata, Toshihumi Hibi, Hiromasa Ishii

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A second-line chemotherapy for advanced gastric cancer has not been established. We report a case of good response in a 39-year-old woman who had recurrent pleural effusion and positive cytology of type 4 gastric cancer and was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with weekly taxane. After a partial response for type 4 gastric cancer from the treatment with 2 courses of TS-1 plus low-dose cisplatinum (CDDP), followed by outpatient chemotherapy with TS-1 alone or TS-1 plus weekly CDDP, left pleural effusion appeared and CA19-9 increased during the 7th course of the chemotherapy. Cytology of the effusion was class IV. The patient was treated with a course of TS-1 (120 mg/day, day 1-21) plus paclitaxel (50 mg/m2, day 1, 8) followed by 2 week washout. In the following courses, paclitaxel was replaced with docetaxel (30 mg/m2, day 1 and 8) and the course was continued in the outpatient setting. After 2 courses, the left pleural effusion disappeared and remained absent after 6 courses. Gastric biopsy showed no cancer cells and abdominal CT showed no recurrence. Serum CA19-9 doubled 1 week after taxane treatment and decreased gradually week by week during the course. This case suggests that a combination of TS-1 and taxane is effective against recurrent pleural effusion of advanced gastric cancer and useful as a second-line chemotherapy.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number3
Publication statusPublished - 2004 Mar

Fingerprint

Pleural Effusion
Stomach Neoplasms
Cell Biology
Drug Therapy
docetaxel
Paclitaxel
Outpatients
titanium silicide
taxane
Stomach
Biopsy
Recurrence
Therapeutics
Serum
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy. / Akiba, Yasutada; Yamagishi, Yoshiyuki; Mori, Syuka; Ueda, Tomoki; Suzuki, Junji; Hosoe, Naoki; Izumiya, Mikiko; Takaishi, Hiromasa; Nagata, Hiroshi; Hibi, Toshihumi; Ishii, Hiromasa.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 3, 03.2004, p. 453-456.

Research output: Contribution to journalArticle

Akiba, Yasutada ; Yamagishi, Yoshiyuki ; Mori, Syuka ; Ueda, Tomoki ; Suzuki, Junji ; Hosoe, Naoki ; Izumiya, Mikiko ; Takaishi, Hiromasa ; Nagata, Hiroshi ; Hibi, Toshihumi ; Ishii, Hiromasa. / A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 3. pp. 453-456.
@article{8899dad44648405d9b5fbaf870d1f637,
title = "A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy",
abstract = "A second-line chemotherapy for advanced gastric cancer has not been established. We report a case of good response in a 39-year-old woman who had recurrent pleural effusion and positive cytology of type 4 gastric cancer and was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with weekly taxane. After a partial response for type 4 gastric cancer from the treatment with 2 courses of TS-1 plus low-dose cisplatinum (CDDP), followed by outpatient chemotherapy with TS-1 alone or TS-1 plus weekly CDDP, left pleural effusion appeared and CA19-9 increased during the 7th course of the chemotherapy. Cytology of the effusion was class IV. The patient was treated with a course of TS-1 (120 mg/day, day 1-21) plus paclitaxel (50 mg/m2, day 1, 8) followed by 2 week washout. In the following courses, paclitaxel was replaced with docetaxel (30 mg/m2, day 1 and 8) and the course was continued in the outpatient setting. After 2 courses, the left pleural effusion disappeared and remained absent after 6 courses. Gastric biopsy showed no cancer cells and abdominal CT showed no recurrence. Serum CA19-9 doubled 1 week after taxane treatment and decreased gradually week by week during the course. This case suggests that a combination of TS-1 and taxane is effective against recurrent pleural effusion of advanced gastric cancer and useful as a second-line chemotherapy.",
author = "Yasutada Akiba and Yoshiyuki Yamagishi and Syuka Mori and Tomoki Ueda and Junji Suzuki and Naoki Hosoe and Mikiko Izumiya and Hiromasa Takaishi and Hiroshi Nagata and Toshihumi Hibi and Hiromasa Ishii",
year = "2004",
month = "3",
language = "English",
volume = "31",
pages = "453--456",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy

AU - Akiba, Yasutada

AU - Yamagishi, Yoshiyuki

AU - Mori, Syuka

AU - Ueda, Tomoki

AU - Suzuki, Junji

AU - Hosoe, Naoki

AU - Izumiya, Mikiko

AU - Takaishi, Hiromasa

AU - Nagata, Hiroshi

AU - Hibi, Toshihumi

AU - Ishii, Hiromasa

PY - 2004/3

Y1 - 2004/3

N2 - A second-line chemotherapy for advanced gastric cancer has not been established. We report a case of good response in a 39-year-old woman who had recurrent pleural effusion and positive cytology of type 4 gastric cancer and was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with weekly taxane. After a partial response for type 4 gastric cancer from the treatment with 2 courses of TS-1 plus low-dose cisplatinum (CDDP), followed by outpatient chemotherapy with TS-1 alone or TS-1 plus weekly CDDP, left pleural effusion appeared and CA19-9 increased during the 7th course of the chemotherapy. Cytology of the effusion was class IV. The patient was treated with a course of TS-1 (120 mg/day, day 1-21) plus paclitaxel (50 mg/m2, day 1, 8) followed by 2 week washout. In the following courses, paclitaxel was replaced with docetaxel (30 mg/m2, day 1 and 8) and the course was continued in the outpatient setting. After 2 courses, the left pleural effusion disappeared and remained absent after 6 courses. Gastric biopsy showed no cancer cells and abdominal CT showed no recurrence. Serum CA19-9 doubled 1 week after taxane treatment and decreased gradually week by week during the course. This case suggests that a combination of TS-1 and taxane is effective against recurrent pleural effusion of advanced gastric cancer and useful as a second-line chemotherapy.

AB - A second-line chemotherapy for advanced gastric cancer has not been established. We report a case of good response in a 39-year-old woman who had recurrent pleural effusion and positive cytology of type 4 gastric cancer and was treated with TS-1, a DPD inhibitory fluoropyrimidine, in combination with weekly taxane. After a partial response for type 4 gastric cancer from the treatment with 2 courses of TS-1 plus low-dose cisplatinum (CDDP), followed by outpatient chemotherapy with TS-1 alone or TS-1 plus weekly CDDP, left pleural effusion appeared and CA19-9 increased during the 7th course of the chemotherapy. Cytology of the effusion was class IV. The patient was treated with a course of TS-1 (120 mg/day, day 1-21) plus paclitaxel (50 mg/m2, day 1, 8) followed by 2 week washout. In the following courses, paclitaxel was replaced with docetaxel (30 mg/m2, day 1 and 8) and the course was continued in the outpatient setting. After 2 courses, the left pleural effusion disappeared and remained absent after 6 courses. Gastric biopsy showed no cancer cells and abdominal CT showed no recurrence. Serum CA19-9 doubled 1 week after taxane treatment and decreased gradually week by week during the course. This case suggests that a combination of TS-1 and taxane is effective against recurrent pleural effusion of advanced gastric cancer and useful as a second-line chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=1642525280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642525280&partnerID=8YFLogxK

M3 - Article

C2 - 15045961

AN - SCOPUS:1642525280

VL - 31

SP - 453

EP - 456

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 3

ER -